{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2021_00017673", "CSN": null, "TRF": "ORD_1247966_01", "MRN": "47518047", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "942186", "clinicalId": "943570", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1247966_01", "SampleName": "US1201394.01", "Version": "0", "Sample": {"FM_Id": "ORD_1247966_01", "SampleId": "US1201394.01", "BlockId": "nan", "TRFNumber": "ORD_1247966_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2021_11_29", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "Cannot Be Determined", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S110-94773", "MRN": "47518047", "FullName": "\u738b\u6d77\u6b23", "FirstName": "Hai_Hsin", "LastName": "Wang", "SubmittedDiagnosis": "Pancreatic adenocarcinoma (From clinical diagnosis)", "Gender": "Female", "DOB": "1980_09_11", "OrderingMD": "\u8a31\u52ad\u69ae", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2021_11_25", "ReceivedDate": "2021-12-10 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Pancreatic Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "5", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "FLT3", "isVUS": "true", "variantName": "G64R"}, {"geneName": "NTRK1", "isVUS": "true", "variantName": "S396L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of bTMB levels in pancreatic carcinoma are limited (PubMed, Jul 2021). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2021). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). However, the tumor fraction estimate in this sample could not be determined with confidence. Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with high tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results (Li et al., 2021; AACR Abstract 2231). However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "1", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "2", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "3", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "4", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "5", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "6", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "7", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "8", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "9", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "10", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "11", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "12", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "13", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "14", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "15", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "16", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "17", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "18", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "19", "ReferenceId": "29367431", "FullCitation": "Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431", "Include": "true"}, {"number": "20", "ReferenceId": "29056344", "FullCitation": "Campbell BB, et al. Cell (2017) pmid: 29056344", "Include": "true"}, {"number": "21", "ReferenceId": "29329208", "FullCitation": "Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208", "Include": "true"}, {"number": "22", "ReferenceId": "29523759", "FullCitation": "Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759", "Include": "true"}, {"number": "23", "ReferenceId": "23029359", "FullCitation": "Laghi L, et al. PLoS ONE (2012) pmid: 23029359", "Include": "true"}, {"number": "24", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "25", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "26", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "27", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "28", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "29", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "30", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "31", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "32", "ReferenceId": "19659756", "FullCitation": "Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756", "Include": "true"}, {"number": "33", "ReferenceId": "22714864", "FullCitation": "Pande M, et al. Fam. Cancer (2012) pmid: 22714864", "Include": "true"}, {"number": "34", "ReferenceId": "17920897", "FullCitation": "Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897", "Include": "true"}, {"number": "35", "ReferenceId": "19466295", "FullCitation": "Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295", "Include": "true"}, {"number": "36", "ReferenceId": "24978665", "FullCitation": "Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665", "Include": "true"}, {"number": "37", "ReferenceId": "16136383", "FullCitation": "Fam. Cancer (2005) pmid: 16136383", "Include": "true"}, {"number": "38", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "39", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "40", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "41", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "42", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "43", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "44", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "45", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "46", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "47", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "48", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "49", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "50", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "51", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "52", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "53", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2021_12_07 01:10:07", "OpName": "Naomi Lynn Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Naomi Lynn Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "PANCREAS", "disease_ontology": "Pancreas ductal adenocarcinoma", "flowcell_analysis": "2000019056", "gender": "female", "pathology_diagnosis": "pancreatic adenocarcinoma", "pipeline_version": "v3.8.2", "purity_assessment": "11.0", "specimen": "ORD_1247966_01*US1201394.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1247966_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1201394.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4962", "cds_effect": "1187C>T", "depth": "6761", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "49.62", "position": "chr1:156844184", "protein_effect": "S396L", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1201394.01_1"}}, {"allele_fraction": "0.4851", "cds_effect": "190G>A", "depth": "1313", "equivocal": "false", "functional_effect": "missense", "gene": "FLT3", "percent_reads": "48.51", "position": "chr13:28636182", "protein_effect": "G64R", "status": "unknown", "strand": "_", "transcript": "NM_004119", "dna_evidence": {"sample": "SQ_US1201394.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "18", "status": "unknown", "dna_evidence": {"sample": "SQ_US1201394.01_1"}}, {"organism": "HHV_4", "reads_per_million": "21", "status": "unknown", "dna_evidence": {"sample": "SQ_US1201394.01_1"}}, {"organism": "HHV_8", "reads_per_million": "11", "status": "unknown", "dna_evidence": {"sample": "SQ_US1201394.01_1"}}]}}}}}